Systemic therapy strategies for head-neck carcinomas: Current status.

Area of Science:

• Oncology
• Head and Neck Surgery
• Medical Oncology

Background:

• Head and neck cancers, primarily squamous cell tumors, have poor prognoses due to recurrences and metastases.
• Standard treatments (surgery, radiation) are insufficient, necessitating effective systemic therapies.

Purpose of the Study:

• To review current and emerging systemic treatment strategies for head and neck cancers.
• To evaluate the efficacy, toxicity, and quality-of-life implications of various systemic modalities.

Main Methods:

• Review of established chemotherapy regimens, including induction and neoadjuvant protocols.
• Analysis of targeted therapies, such as EGFR-specific antibodies, and novel biologicals (signal cascade inhibitors, genetic agents, immunotherapies).
• Consideration of treatment evaluation criteria: efficacy, toxicity, quality-of-life, and predictive biomarkers.

Main Results:

• Chemotherapy is established for palliative and curative-intent treatment (chemoradiotherapy).
• Triple-combination induction therapy shows high remission rates but significant toxicity.
• Targeted therapies and novel biologicals are under investigation for advanced, recurrent, or metastatic disease.

Conclusions:

• Systemic therapies are essential complements to local treatments for head and neck cancers.
• Balancing efficacy, toxicity, quality-of-life, and biomarkers is key for individualized treatment.
• Emerging targeted and biological therapies hold promise for improving patient outcomes.